Overview and Definitional Shifts

Idiopathic Nephrotic Syndrome is the most frequent glomerular disease of childhood, characterized by heavy proteinuria ($\text{uPCR} > 2.0\text{ mg/mg}$ or $> 300\text{ mg/dL}$ / $3+$ on dipstick), hypoalbuminemia ($< 2.5\text{ g/dL}$), generalized edema, and hyperlipidemia. The International Pediatric Nephrology Association (IPNA, 2022–2023 Guidelines) updated clinical practice recommendations, establishing shorter steroid courses, biomarker-driven genetic screening, and standardized biologic protocols.


IPNA Core Clinical Classifications

flowchart TD
    A["Child with First Episode Nephrotic Syndrome<br/>(uPCR > 2.0 mg/mg, Albumin < 2.5 g/dL, Edema)"] --> B["Induction Prednisolone Therapy:<br/>60 mg/m2/day (max 60 mg) for 4–6 Weeks"]
    
    B --> C{"Urine Protein Negative/Trace at 4 Weeks?"}
    
    C -->|Yes: Complete Remission| D["Steroid-Sensitive Nephrotic Syndrome (SSNS)"]
    D --> E["Taper Prednisolone on Alternate Days for 4–6 Weeks<br/>(Total Duration: 8–12 Weeks Total)"]
    
    C -->|No: Persistent Proteinuria| F["Steroid-Resistant Nephrotic Syndrome (SRNS)"]
    F --> G["Genetic Testing (NGS Podocyte Panel)<br/>BEFORE Invasive Kidney Biopsy"]
Clinical PhenotypeDiagnostic Definition (IPNA Criteria)
Steroid-Sensitive (SSNS)Complete remission achieved within 4 weeks of daily prednisolone ($60\text{ mg/m}^2/\text{day}$). Remission is defined as urinary protein-to-creatinine ratio ($\text{uPCR}$) $< 0.2\text{ mg/mg}$ or negative/trace dipstick for 3 consecutive days.
Steroid-Resistant (SRNS)Failure to achieve complete remission after 4 weeks of daily prednisolone at full dose. (IPNA formally deprecated the older historical 8-week definition [4 weeks daily + 4 weeks alternate-day] to avoid unnecessary high-dose steroid toxicity).
Frequently Relapsing (FRNS)$\ge 2$ relapses within 6 months of initial response, OR $\ge 4$ relapses within any 12-month period.
Steroid-Dependent (SDNS)$\ge 2$ consecutive relapses occurring during steroid dose tapering or within 14 days of steroid cessation.

Shortened Initial Steroid Regimen

Clinical Evidence: The PREDNOS and Pedi-RCR Trials

  • Historically, international protocols prescribed 12 to 24 weeks of initial steroids to reduce relapses.
  • Landmark multicenter randomized controlled trials (PREDNOS trial, Lancet 2019; Pedi-RCR trial) proved that extending steroid therapy beyond 8 to 12 weeks does not reduce the rate of subsequent relapses, the proportion of frequent relapsers, or time to first relapse.
  • Current IPNA Recommendation:
    • Daily Prednisolone: $60\text{ mg/m}^2/\text{day}$ (max $60\text{ mg}$) for 4 to 6 weeks.
    • Followed by Alternate-Day Prednisolone: $40\text{ mg/m}^2$ on alternate days for 4 to 6 weeks.
    • Total Course: 8 to 12 weeks. This minimizes growth failure, bone demineralization, Cushingoid habitus, and behavioral disturbances.

Steroid-Sparing Strategies in FRNS / SDNS

For children who develop steroid dependency or frequent relapses, steroid-sparing maintenance agents are indicated to maintain sustained remission while sparing linear growth:

AgentMechanismDosing & RegimenClinical Monitoring & Caveats
LevamisoleImmunomodulator; stimulates Th1 cytokines and glucocorticoid receptor expression$2.5\text{ mg/kg}$ on alternate days for 12 to 24 monthsFirst-line steroid-sparing agent for mild SDNS/FRNS. Excellent safety profile. Monitor CBC every 8–12 weeks to detect rare reversible neutropenia / agranulocytosis or ANCA vasculitis.
Mycophenolate Mofetil (MMF)Inhibits inosine monophosphate dehydrogenase (IMPDH), blocking de novo purine synthesis in lymphocytes$1,200\text{ mg/m}^2/\text{day}$ orally in two divided doses ($30–40\text{ mg/kg/day}$)Highly effective in sustaining remission and tapering steroids. Measure mycophenolic acid (MPA) 12-hour AUC (target: $> 30–60\ \mu\text{g}\cdot\text{h/mL}$); monitor for diarrhea and leukopenia.
Calcineurin Inhibitors (CNIs) (Tacrolimus, Cyclosporine)Inhibits calcineurin phosphatase, preventing IL-2 transcription in T cells; stabilizes podocyte synaptopodinTacrolimus: $0.1–0.15\text{ mg/kg/day}$ (12-hour trough target: $4–8\text{ ng/mL}$).
Cyclosporine: $4–5\text{ mg/kg/day}$ (trough $80–120\text{ ng/mL}$).
Powerful antiproteinuric effect; first-line therapy for SRNS. Chronic risk of nephrotoxicity (tubular atrophy, interstitial fibrosis); protocol kidney biopsy recommended after 2–3 years of continuous therapy.

Targeted Biologic Therapy: Rituximab and Anti-CD20 Monoclonal Antibodies

flowchart TD
    A["Indications for Rituximab:<br/>1. Difficult / Complicated SDNS failing oral steroid-sparing agents (MMF / Levamisole)<br/>2. Calcineurin Inhibitor Dependence or Nephrotoxicity<br/>3. Severe steroid toxicity (growth failure, cataracts, severe osteopenia)"] --> B["Pre-Treatment Screening:<br/>• Total Serum IgG & IgM (Pre-existing hypogammaglobulinemia)<br/>• Hepatitis B & Latent Tuberculosis screening<br/>• Baseline CD19+ B-cell quantification"]
    
    B --> C["Administration Protocol:<br/>Single Dose: 375 mg/m2 IV Infusion<br/>(Premedicate with Paracetamol + Antihistamine + Methylprednisolone)"]
    
    C --> D["Post-Infusion Monitoring:<br/>• Flow cytometry at 48–72h: Confirm complete B-cell depletion (CD19 < 1%)<br/>• Serial CD19 tracking every 1–2 months"]
    
    D --> E{"Clinical Course"}
    E -->|"Sustained Remission"| F["Maintain off all oral immunosuppression / steroids"]
    E -->|"B-cell Recovery (> 1%) + Clinical Relapse"| G["Consider repeat single-dose Rituximab"]

1. Dosing Protocols

  • Single-Dose Protocol: An initial single infusion of $375\text{ mg/m}^2$ achieves complete peripheral CD19+ B-cell depletion ($<1\%$ of total lymphocytes) in $>95\%$ of pediatric patients, providing equivalent 1-year remission rates compared to older 4-dose weekly regimens while reducing cost and adverse events.
  • Efficacy: Induces complete, medication-free remission in $> 70–80\%$ of children with complicated SDNS, halts steroid-induced growth deceleration, and enables withdrawal of CNIs.
  • Repeat Dosing Strategy: Redosing is guided by clinical relapse rather than preemptively at the time of B-cell reconstitution.

2. Adverse Events and Safety Surveillance

  • Infusion Reactions: Fever, chills, bronchospasm, urticaria; managed via premedication.
  • Secondary Hypogammaglobulinemia: Occurs in $10–20\%$ of children, particularly those aged $<5$ years. Baseline serum IgG must be quantified; if profound post-infusion IgG drop occurs ($<300–400\text{ mg/dL}$), replacement Intravenous Immunoglobulin (IVIG) is required to prevent life-threatening encapsulated bacterial infections.
  • Second-Generation Agent (Ofatumumab): Fully human anti-CD20 mAb binding a distinct epitope; indicated for patients with refractory disease who develop neutralizing anti-rituximab antibodies.

Genetic Testing in Steroid-Resistant Nephrotic Syndrome (SRNS)

"Genetics First" Diagnostic Algorithm

IPNA guidelines mandate comprehensive Next-Generation Sequencing (NGS) podocyte gene panels (NPHS1 [Nephrin], NPHS2 [Podocin], WT1, LAMB2, PLCE1, ACTN4, INF2) prior to performing a percutaneous kidney biopsy, especially in:

  1. Congenital nephrotic syndrome (onset $< 3\text{ months}$).
  2. Infantile nephrotic syndrome (onset $3–12\text{ months}$).
  3. Children with family history of consanguinity or nephrotic syndrome.
  4. Primary steroid resistance with syndromic extra-renal features (Frasier, Denys-Drash, Pierson, Schimke syndromes).

Clinical Consequences of Identifying a Genetic Podocytopathy

  1. Immediate Cessation of Immunosuppression: Monogenic podocyte structural mutations do not respond to steroids, CNIs, or rituximab. Withdrawing toxic immunosuppression prevents futile drug exposure.
  2. Post-Transplant Recurrence Prediction: Genetic SRNS carries an extremely low risk of disease recurrence in a kidney allograft ($< 5\%$), whereas non-genetic immunological SRNS carries a high recurrence risk of $30–50\%$.